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Abstract
Background: Helicobacter pylori is a common pathogen, and its prevalence varies with socioeconomic conditions (10–80%). It
has recently been recognized as a class I carcinogen in relation to gastric cancer. The aim of this study was to investigate the
presence of Helicobacter pylori in neoplasms of the colon by immunohistochemical methods.
Methods: The polypectomy materials of 51 patients (19 male and 32 female) who had undergone colonoscopic polypectomy
were retrieved for retrospective examination. The endoscopic size and colonic localization of the polyps were recorded.
Hematoxylin and eosin stains were evaluated according to histological type and grade of dysplasia. Biopsy stains were
immunohistochemically treated with Helicobacter pylori antibodies by the streptavidine-biotin immunoperoxidase technique.
Helicobacter pylori staining in the gastric mucosa was used as the control for the immunohistochemical method. Specimens were
classified according to the presence of Helicobacter pylori under an optical microscope, and Helicobacter pylori positive specimens
were stratified according to the respective staining pattern.
Results: Mean age was 61.88 ± 10.62 (40–82) years. Polyp sizes were 1.45 ± 0.92 (1–4) cm; and 25.5% of polyps were localized
in the right colon, 68.6% in the left colon and 5.9% in the transverse colon. Presence of Helicobacter pylori was not correlated
with localization (p > 0.05) or size of the polyps (p > 0.05).
Eleven (21.6%) of all specimens included in the study were Helicobacter pylori positive by immunohistochemical methods. Of the
Helicobacter pylori positive specimens, the staining pattern was diffuse: Equivocal in 90.9%, nonspecific with a finely granular type
concentrated on the luminal surface in 90.9%, dot-like granular in 54.5%, and spiral in 9.1%. Of the tubular polyps, 17.9% were
H. pylori positive, and the staining pattern was equivocal in 100%, luminal in 85.7%, and dot-like granular in 57.1%. Of the villous
polyps, 60% were H. pylori positive, and the staining pattern was inconclusive in 66.7%, luminal in 100%, dot-like granular in 33.3%,
and spiral in 33.3%. Of the cancerous cases, 25% were H. pylori positive and showed an equivocal, luminal, and dot-like granular
staining pattern. No significant correlation was determined between histologic types and prevalence of H. pylori (p > 0.05).
Conclusion: The presence of H. pylori in colon polyps did not yield any correlation with polyp size, colonic localization or
histopathologic type. The higher rate of H. pylori positivity in villous polyps does not present a causal relationship. We were able
to determine H. pylori existence in colon polyps by immunohistochemical methods, albeit with no statistical significance.
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Background
Helicobacter pylori (H. pylori) is a class I carcinogen giving
rise to gastric adenocarcinoma [1,2]. In humans, apart
from the gastric mucosa, it has been isolated from choles-
tatic liver parenchyma [3]. Experimental studies have
demonstrated a relationship between certain Helicobacter
species with inflammatory bowel disease and colonic ade-
nocarcinoma development [4-6]. H. pylori infections have
been considered as a risk factor for development of color-
ectal neoplasms (CRNs) such as colon polyps and colon
cancer (CC) due to the high prevalence of serologically
positive H. pylori infection among CRN patients in some
uncontrolled studies [4,7,8]. Nonetheless, data pertaining
to the association between CRN and H. pylori is limited
and insufficient. Even though there exist human studies
that support [7,9] or reject [10,11] a relationship between
CRN and H. pylori, a direct colonization of the colon by H.
pylori that would suggest a causal role for CRN has not
been shown [4,7,8]. In this study, the presence of H. pylori
in CRNs, and a potential relationship with histopatho-
logic types of the neoplasms by immunohistochemical
(IHC) methods specific to H. pylori was investigated.
Methods
Biopsy specimens of 51 patients (19 female and 32 male)
who had been administered polypectomy following
detection of polyps by colonoscopy were included in the
analysis. Pseudopolyps in inflammatory bowel diseases,
inflammatory polyps, juvenile polyposis syndrome,
familial adenomatous polyposis and colon neoplasms
that did not appear polypoid by endoscopy or colon car-
cinomas were excluded. Polyps in all colonic localizations
were included. Polyps localized in the descending colon,
sigmoid colon and rectum were classified as 'left colon',
those in the transverse colon as 'transverse colon' and
those in the cecum and ascending colon as 'right colon'
localization. The mean age of the patients was 61.88 ±
10.62 years (range: 40–82 years). Endoscopic polyp size
and localization were categorized. Haematoxylin and
eosin (H&E) stains obtained from paraffin blocks were
retrospectively evaluated by two pathologists and classi-
fied according to histopathologic type and degree of dys-
plasia. In the IHC analysis following this assessment of
the H&E stains, specimens were treated with H. pylori anti-
bodies (ready to use, polyclonal, Biogen, Union City, CA,
USA) by the streptavidine-biotin immunoperoxidase
technique. Specimens were incubated with primary anti-
body at a dilution of 200 μg/ml at room temperature for
twenty minutes [12]. The control testing for the IHC
method consisted of H. pylori staining in the gastric
mucosa (Figure 1, 2). H. pylori positive specimens were
separated according to the IHC staining pattern of H.
pylori under optical microscopy. An institutional ethics
committee approval was obtained prior to initiation of
the study.
Statistical Analysis
To perform the statistical analyses, descriptive statistical
methods, the Kruskal-Wallis test, the Mann-Whitney U
test, and the chi-square test were used. Results were evalu-
ated at a 95% confidence interval; and a p < 0.05 value
was recognized as the statistical significance level.
Results
During endoscopic investigation, polyp sizes were 1.45 ±
0.92 cm (range: 1–4 cm), 25.5% of the polyps were local-
ized in the right colon, 68.6% in the left colon and 5.9%
in the transverse colon. H. pylori positivity/negativity in
Immunohistochemical H. pylori positivity in gastric control  biopsies (×40) Figure 1
Immunohistochemical H. pylori positivity in gastric control 
biopsies (×40).
Immunohistochemical H. pylori positivity in gastric control  biopsies (×40) Figure 2
Immunohistochemical H. pylori positivity in gastric control 
biopsies (×40).BMC Gastroenterology 2008, 8:35 http://www.biomedcentral.com/1471-230X/8/35
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the polyps was not correlated to localization in the colon
(p > 0.05) or polyp size (p > 0.05). The distribution of his-
topathologic types was 76.5% tubular, 9.8% villous, 5.9%
tubulovillous, and 7.8% adenocarcinoma. Of the 39
tubular cases, 38 (97.4%) had low grade dysplasia (LGD)
and 1 (2.6%) high grade dysplasia (HGD); of the 5 villous
polyps, 1 (20%) had LGD and 4 (80%) HGD; and finally,
all 3 (100%) of the tubulovillous polyps had LGD. Aden-
ocarcinoma was established in four polyps.
11 (21.6%) of the polyps were determined to be H. pylori
positive by IHC evaluation. Of these 11 specimens, 10
(90.9%) had an equivocal diffuse mucosal staining pat-
tern, 10 (90.9%) had nonspecific finely granular staining
concentrated on the luminal surface (Figure 3), and 6
(54.5%) also had a dot-like granular staining pattern. The
weak dark yellow/light brown staining in a spiral form in
1 (9.1%) specimen was evaluated as positive (Figure 4, 5).
Staining patterns of H. pylori positive specimens according
to histopathological polyp types are summarized in Table
1.
The prevalence of H. pylori was higher in villous type pol-
yps (60%) compared to other histologic types, but this
difference was not statistically significant. We were not
able to establish a significant correlation between the pol-
yps' histologic types and the prevalence of H. pylori (p >
0.05).
Discussion
Epidemiological studies have confirmed a causal relation-
ship between H. pylori and gastric cancer [13,14] and
colonic phenotype of H. pylori related intestinal metapla-
sia (IM) has been associated with gastric cancer [1,15].
Thus, association of H. pylori in various gastrointestinal
system organ cancers has been investigated and Helico-
bacter DNAs were positive in 52.6% of the hepatobiliary
cancer cases. This positivity suggests that Helicobacter spe-
cies may play a role in the pathogenesis of hepatobiliary
cancer through an acceleration of biliary cell kinetics [16].
Helicobacter species, which may colonize the biliary tract,
have been implicated as a possible cause of hepatobiliary
diseases ranging from chronic cholecystitis and primary
sclerosing cholangitis to gall-bladder carcinoma and pri-
mary hepatic carcinomas [17]. Therefore the hypothesis
that  H. pylori would also be associated with intestinal
polypoid structures needs to be investigated. Further-
more, there exist several studies demonstrating the co-
existence of CRNs and H. pylori seropositivity supports
this suggestion. The potential mechanism of the signifi-
cant association between colon polyps and serologic H.
pylori positivity has been attributed to the remote trophic
effect of the elevated gastrin level on the colonic mucosa
[9]. This study has been designed as to investigate an asso-
ciation between H. pylori and extragastric intestinal neo-
plasms and colonization in cases of direct colonic
dysplasia has been investigated by specific IHC methods.
Shmuely et al. reported that H. pylori CagA+ seropositivity
is enhanced in gastric and colon cancers [18], while Fire-
man et al. demonstrated a correlation between H. pylori
seropositivity and CA19-9 elevation in patients with CC
[19]. In the evaluation by Mizuno et al. of the colon
pathologies of 332 patients with high-resolution colonos-
copy, the increase in the incidence of adenomatous pol-
yps in H. pylori IgG seropositive patients and diminution
of normal colonoscopy findings was found more signifi-
cant than in seronegative patients [20]. While the under-
lying mechanism is not clear, the prevalence of gastric H.
pylori infection was found to be increased, especially in
colonic adenomas (71.4% in polyps, 55% in cancers)
[21]. In case reports of Cap polyposis that support the cor-
relation between CRN and H. pylori, despite the inability
to demonstrate H. pylori in polyps by IHC methods, erad-
ication of the infection led to improvements in symptoms
and polyps [22,23]. Although direct and indirect relation-
ship between H. pylori and CRNs have been widely recog-
nized, only the relationship between the presence of
serologically positive H. pylori and CRNs have been dem-
onstrated [4,8]. It has also been reported that the remote
and local consequences of H. pylori infection might also
have a synergistic effect on the emergence or development
of these neoplasms under certain conditions [4,8]. A study
of 374 patients with GI cancers evaluated serologic H.
Table 1: Positivity for H. pylori and staining patterns according to histopathologic type
Tubular (n = 7) Villous (n = 3) Cancer (n = 1)
n (%) n (%) n (%)
H. pylori presence (p = 0.137)
Positive 17.9% 60.0% 25.0%
Negative 82.1% 40.0% 75.0%
Staining patterns of H. pylori (+) specimens
Equivocal 7 (100%) 2 (66.7%) 1 (100%)
Luminal 6 (85.7%) 3 (100%) 1 (100%)
Dot-like Granular 4 (57.1%) 1 (33.3%) 1 (100%)
Spiral - 1 (33.3%) -BMC Gastroenterology 2008, 8:35 http://www.biomedcentral.com/1471-230X/8/35
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pylori positivity according to localization, serologic H.
pylori positivity was found to be unrelated to CC localiza-
tion [24]. In an investigation for H. pylori specific 16S
rDNA with PCR in CC biopsies, Grahn et al. revealed H.
pylori DNA in 27% of cancer tissue specimens. They could
not ascertain any correlation between H. pylori positivity
and the stage or colonic localization of the cancer [25].
We also found no association with the size or colonic
localization of polyps determined to be H. pylori positive
by IHC methods.
In a study by Bulajic et al. on 83 subjects with CC that
investigated H. pylori DNA by PCR in biopsy specimens
from CC and normal mucosal tissues, H. pylori IgG anti-
body was positive in 36 patients while H. pylori was deter-
mined by PCR in the tissues of 1 patient with CC and 5
specimens of normal mucosa. However, no correlation
between  H. pylori positivity and CC could be demon-
strated [10]. There exist serologic and colon tissue PCR
studies that support [11,20,26] or reject [5,10,27] a corre-
lation between H. pylori and CRNs.
The Giemsa staining method is specific for the determina-
tion of gastric spiral forms of the organism. However, IHC
methods have been found to better identify non-spiral
forms of the bacterium [7,28-32]. It has been suggested
that a dot-like staining pattern with the IHC method rep-
resents the coccoid form of H. pylori, and this method of
staining makes it impossible to differentiate mucus or
debris on the lumen from antigenic structures with H.
pylori-like reactions or stain precipitates. Although IHC
staining is more specific than the Giemsa method rou-
tinely used for the evaluation of gastric H. pylori, false pos-
itives may be difficult to conclusively differentiate
[7,28,29]. In our study, H. pylori showed various staining
patterns with IHC method. Therefore we regarded a dot-
like granular staining pattern as a positive finding together
with the coexistence of other luminal or equivocal stain-
ing patterns.
Similar to our study, in a trial investigating presence of H.
pylori in colon polyps by IHC methods, H. pylori was deter-
mined in tubular and tubulovillous adenomas, but not in
villous polyps. This result was deemed insignificant and
interpreted to be potentially related to the micro-environ-
ment [7]. Similarly, as with the low prevalence of H. pylori
in gastric IM sites or some gastric fundic polyps, the
Nonspecific finely granular staining concentrated on the lumi- nal surface by IHC staining (×40) Figure 3
Nonspecific finely granular staining concentrated on the lumi-
nal surface by IHC staining (×40).
Spiral-form dark yellow/light brown staining in lumen of ade- nomatous polyp (×40) Figure 4
Spiral-form dark yellow/light brown staining in lumen of ade-
nomatous polyp (×40).
Spiral-form dark yellow/light brown staining in lumen of ade- nomatous polyp (×40) Figure 5
Spiral-form dark yellow/light brown staining in lumen of ade-
nomatous polyp (×40).BMC Gastroenterology 2008, 8:35 http://www.biomedcentral.com/1471-230X/8/35
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micro-lining in villous adenomas may also be inoppor-
tune for H. pylori[7,33]. Contrary to this finding, we found
a higher prevalence of H. pylori positivity in villous polyps
compared with other histologic types. A similar situation
is present within studies investigating presence of H. pylori
in gastric IM [34,35]. Whilst some studies support the
assumption that H. pylori is absent in gastric IM; in studies
using IHC method presence of H. pylori in gastric IM have
been demonstrated [28,33,36]. Furthermore, the absence
of H. pylori in villous adenomas as reported by several
authors does not necessarily indicate the lack of an associ-
ation, as this might be supportive of the hypothesis about
H. pylori migration after development of the lesion
[7,28,37]. Despite reports of positivity for H. pylori in
tubular and tubulovillous adenomas [7] and the lack of a
significant association with cellular types of polyps in our
study, reports that have directly demonstrated the pres-
ence of H. pylori in villous adenomas (60%) by IHC meth-
ods exist in medical literature. The small number of
materials in our study may account for the lack of statisti-
cal significance. However, the lack of a correlation
between cellular types of polyps and H. pylori presence
indicates that the micro-environment may indeed have a
role, and H. pylori strains may vary.
Conclusion
This study has demonstrated the presence of H. pylori in
colon polyps by IHC methods, albeit with no statistical
significance. Our findings do not suffice for the assertion
of a definitive association between H. pylori positivity and
CRNs. However, even in the absence of a causal relation-
ship, our results are suggestive of a correlation between
colon polyps and H. pylori. Further cellular studies that are
supported by molecular biological techniques are needed
to clarify the presence or absence of such an association.
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